Get the Stockscreener App
32.68
3.98%
1.25
Pre-market:
33.70
1.02
+3.12%
Ionis Pharmaceuticals Inc stock is traded at $32.68, with a volume of 1.49M.
It is up +3.98% in the last 24 hours and down -8.28% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$31.43
Open:
$31.62
24h Volume:
1.49M
Relative Volume:
1.06
Market Cap:
$5.16B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-13.39
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-0.03%
1M Performance:
-8.28%
6M Performance:
-31.66%
1Y Performance:
-35.90%
1-Day Range:
$31.47
$32.95
1-Week Range:
$31.40
$33.90
52-Week Range:
$31.40
$52.49
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
32.68 | 5.16B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Assenagon Asset Management S.A. Purchases 128,619 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat
Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN
Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals EVP sells $213,889 in stock By Investing.com - Investing.com UK
Ionis Pharmaceuticals EVP sells shares worth $139,855 By Investing.com - Investing.com UK
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
Familial Lipoprotein Lipase Deficiency Market to Continue - openPR
Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from Royal Bank of Canada - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - Marketscreener.com
Ionis enters new chapter in 2025 as commercial-stage biotech wit - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by International Assets Investment Management LLC - MarketBeat
Ionis Pharma stock hits 52-week low at $33.33 amid market challenges - Investing.com Australia
US FDA approves Ionis Pharma's genetic disorder drug - AOL
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year LowShould You Sell? - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Vanguard Group Inc's Strategic Acquisition of Ionis Pharmaceuticals Shares - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conferenc - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Benzinga
Otsuka and Ionis’ donidalorsen accepted for EMA review - The Pharma Letter
Objective long/short (IONS) Report - Stock Traders Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
Ionis Pharmaceuticals Initiates Phase 3 Study of Olezarsen to Treat Severe Hypertriglyceridemia - Marketscreener.com
Ionis Pharmaceuticals director Hayden buys $181k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):